Numinus is a life sciences firm with a deal with psychological well being and wellness. The corporate is engaged in analysis, improvement and supply of protected, evidence-based psychedelic-assisted psychotherapy. We argue that demand for these providers is ready for sturdy progress, pushed by a rising ecosystem of corporations and analysis institutes demonstrating the doubtless advantages of psychedelic-assisted psychotherapies over many current psychological well being therapies, and by rising demand for psychological well being and substance abuse providers in North America (see p3-4) within the post-COVID setting. The corporate has three areas of operational exercise:
Numinus Well being supplies psychedelic-assisted psychotherapy by way of 4 clinics in Canada, with plans for speedy progress. These clinics are growing ketamine-assisted psychotherapy (KAP) protocols for a spread of psychological problems, and are additionally engaged on new compassionate entry trials enabling the introduction of therapies with psilocybin and MDMA below Well being Canada approvals.
Numinus Biosciences operates a licensed laboratory for utilized analysis and IP improvement and R&D partnerships. The corporate holds a federal authorities authorized seller’s license overlaying a number of psychedelic compounds, and in addition to a license to provide and extract psilocybin from mushrooms, and for the testing of hashish merchandise. Numinus Biosciences is a number one supplier of lab providers to the psychedelics and hashish industries.
Numinus R&D is a medical analysis unit growing therapeutic protocols for psychedelic-assisted psychotherapy. These protocols will likely be used for optimizing affected person care below the present KAP therapies, and in defining medical trials packages for future purposes of psychedelic drugs.